MA44054A - Plateforme d'anticorps bispécifique - Google Patents

Plateforme d'anticorps bispécifique

Info

Publication number
MA44054A
MA44054A MA044054A MA44054A MA44054A MA 44054 A MA44054 A MA 44054A MA 044054 A MA044054 A MA 044054A MA 44054 A MA44054 A MA 44054A MA 44054 A MA44054 A MA 44054A
Authority
MA
Morocco
Prior art keywords
bispecific antibody
antibody platform
platform
bispecific
antibody
Prior art date
Application number
MA044054A
Other languages
English (en)
Inventor
Martin Preyer
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA44054A publication Critical patent/MA44054A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA044054A 2015-12-18 2016-12-15 Plateforme d'anticorps bispécifique MA44054A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562269664P 2015-12-18 2015-12-18

Publications (1)

Publication Number Publication Date
MA44054A true MA44054A (fr) 2018-10-24

Family

ID=57681809

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044054A MA44054A (fr) 2015-12-18 2016-12-15 Plateforme d'anticorps bispécifique

Country Status (9)

Country Link
US (1) US11447575B2 (fr)
EP (1) EP3389710A1 (fr)
JP (2) JP7138046B2 (fr)
KR (1) KR20180100136A (fr)
CN (1) CN108601830B (fr)
AU (1) AU2016370821A1 (fr)
CA (1) CA3008840A1 (fr)
MA (1) MA44054A (fr)
WO (1) WO2017106462A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065861T2 (hu) * 2016-08-26 2024-06-28 Sanofi Sa Szelektív könnyûlánc-párosítást elõsegítõ multispecifikus antitestek
CN111356477B (zh) * 2017-08-01 2024-08-30 Ab工作室有限公司 双特异性抗体及其用途
CN110028588A (zh) * 2018-01-11 2019-07-19 上海细胞治疗研究院 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
MX2021004772A (es) 2018-10-29 2021-08-16 Biogen Ma Inc Variantes de fc5 humanizado y estabilizado para mejorar el transporte de la barrera hematoencefalica.
CA3120800A1 (fr) 2018-12-17 2020-06-25 Revitope Limited Recruteur de cellules immunitaires jumelles
CN113692416A (zh) * 2019-03-25 2021-11-23 苏州丁孚靶点生物技术有限公司 蛋白质异二聚体及其用途
JP2022545682A (ja) * 2019-08-23 2022-10-28 アイジーエム バイオサイエンシズ インコーポレイテッド ＩｇＭグリコバリアント
JP2023509212A (ja) * 2020-01-09 2023-03-07 江蘇恒瑞医薬股▲ふん▼有限公司 新型ポリペプチド複合物
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2022237882A1 (fr) * 2021-05-14 2022-11-17 江苏恒瑞医药股份有限公司 Molécule de liaison à l'antigène
EP4377338A2 (fr) 2021-07-27 2024-06-05 Novab, Inc. Anticorps anti-vlrb génétiquement modifiés présentant des fonctions effectrices immunitaires
WO2024073482A1 (fr) * 2022-09-28 2024-04-04 Dren Bio, Inc. Anticorps multispécifiques et leurs procédés d'utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CN103403025B (zh) * 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
US9738707B2 (en) * 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013156054A1 (fr) * 2012-04-16 2013-10-24 Universität Stuttgart Domaine 2 de chaîne lourde d'igm et d'ige en tant que modules d'homodimérisation à liaison covalente pour la génération de protéines de fusion à double spécificité
WO2013174873A1 (fr) 2012-05-24 2013-11-28 F. Hoffmann-La Roche Ag Anticorps multispécifiques
AU2014337135B2 (en) * 2013-10-18 2019-09-19 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
WO2017011342A1 (fr) 2015-07-10 2017-01-19 Abbvie Inc. Protéines de liaison modifiées par igm ou ige et leurs utilisations
HUE065861T2 (hu) * 2016-08-26 2024-06-28 Sanofi Sa Szelektív könnyûlánc-párosítást elõsegítõ multispecifikus antitestek
CA3120800A1 (fr) * 2018-12-17 2020-06-25 Revitope Limited Recruteur de cellules immunitaires jumelles

Also Published As

Publication number Publication date
JP2019502694A (ja) 2019-01-31
US11447575B2 (en) 2022-09-20
KR20180100136A (ko) 2018-09-07
CN108601830A (zh) 2018-09-28
EP3389710A1 (fr) 2018-10-24
US20190048098A1 (en) 2019-02-14
WO2017106462A1 (fr) 2017-06-22
AU2016370821A1 (en) 2018-07-12
CN108601830B (zh) 2023-02-03
JP2021121642A (ja) 2021-08-26
JP7138046B2 (ja) 2022-09-15
CA3008840A1 (fr) 2017-06-22

Similar Documents

Publication Publication Date Title
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA44054A (fr) Plateforme d'anticorps bispécifique
MA47268A (fr) Anticorps anti-gpc3
DK3625259T3 (da) Anti-sirpalpha-antistoffer
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA53434A (fr) Anticorps anti-tigit
MA46041A (fr) Anticorps anti-tim -3
MA46057A (fr) Anticorps anti-ctla4
MA42626A (fr) Nouveaux anticorps anti-pd-1
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA43028A (fr) Anticorps bispécifiques pour pd1 et tim3
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA52884A (fr) Anticorps anti-il-11
MA53297A (fr) Anticorps anti-icos
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
DK3504241T3 (da) Anti-cd3-antistofformuleringer
MA47472A (fr) Anticorps
MA50352A (fr) Anticorps multispécifiques
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA49749A (fr) Anticorps anti-cd137
DK3606961T3 (da) Garp-tgf-beta-antistoffer